MSF treats patients with a liposomal Amphotericin B, sold by Gilead under the brand name AmBisome.
Press release |

Breakthrough in treatment of HIV-related cryptococcal meningitis gives Gilead another opportunity to fulfil its promise to scale up access to lifesaving drug

Following a breakthrough in treatment of HIV-related cryptococcal meningitis, MSF urges Gilead to immediately scale up access to lifesaving drug L-AmB

HIV/AIDS
Read more
Photograph by Misha Friedman

Latest news

Key publications

MSF Access Campaign work on COVID-19

Video thumbnail
MSF International President appeals to governments blocking landmark COVID-19 proposal
Video thumbnail
COVID-19: No patents or profiteering in a pandemic
Video thumbnail
No monopolies - Access to COVID-19 treatment
Video thumbnail
Lives Over Profit: a Patient, a Doctor and a Lawyer Take Action
Video thumbnail
A Snapshot of the Access Campaign

What good is a breakthrough medicine if the people who need it can't afford it?

Lives over profit
20 Years of Advocacy in Action - JOIN US!

Our work

COVID-19
Drug-resistant infections
Diabetes
Hepatitis C
HIV/AIDS
Tropical & neglected diseases
Tuberculosis
Vaccines
Patents & intellectual property
Research & development

Read, watch, share